SCHEMBL21270994

SCHEMBL21270994

CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cccc(C=O)c2)no1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMPD1 P17405 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ BDKRB1 P46663 1/20 0.40
▸ LIPG Q9Y5X9 1/20 0.40
▸ WDR5 P61964 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ GPER1 Q99527 1/20 0.39
▸ MEN1 O00255 1/20 0.37
▸ CFD P00746 2/20 0.37
▸ KIFC1 Q9BW19 1/20 0.37
▸ TAS1R3 Q7RTX0 1/20 0.37
▸ TAS1R1 Q7RTX1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21270997 1.00 SMPD1 (0.43) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270345 0.92 SMPD1 (0.43) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270344 0.92 SMPD1 (0.43) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270449 0.89 SMPD1 (0.46) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270445 0.89 SMPD1 (0.46) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL23375208 0.89 HTT (0.48) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270473 0.87 SMPD1 (0.46) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21284810 0.87 SMPD1 (0.46) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270471 0.87 SMPD1 (0.46) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL30009469 0.87 SMPD1 (0.46) SMPD1NPSR1ALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-11472796-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-10-18 — — US disclosed
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-05-20 — — US disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-11472796-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback